pixelized colorful circle

Your GenAI Antibody Discovery Partner

Your GenAI Antibody Discovery Partner

Converge Bio is accelerating drug development through GenAI-powered innovations in discovery, molecule design, and manufacturing, creating tomorrow's therapies today.

Converge Bio is accelerating drug development through GenAI-powered innovations in discovery, molecule design, and manufacturing, creating tomorrow's therapies today.

Request Access

Speed

Accelerate antibody discovery with Gen AI-powered design and ranking of candidates, significantly shortening timelines by replacing slow, iterative lab work with rapid, guided predictions.

Speed

Accelerate antibody discovery with Gen AI-powered design and ranking of candidates, significantly shortening timelines by replacing slow, iterative lab work with rapid, guided predictions.

Cost

Eliminate costly trial-and-error by rapidly identifying optimal antibody candidates early. Avoid expensive screening cycles and reduce dependence on animal experiments to significantly lower discovery costs.

Cost

Eliminate costly trial-and-error by rapidly identifying optimal antibody candidates early. Avoid expensive screening cycles and reduce dependence on animal experiments to significantly lower discovery costs.

Precision

Engineer antibodies for specificity and developability by integrating epitope, manufacturability and immunogenicity constraints from the start. Reduce risk with optimization of structural and functional fit.

Precision

Engineer antibodies for specificity and developability by integrating epitope, manufacturability and immunogenicity constraints from the start. Reduce risk with optimization of structural and functional fit.

Generate

Predict

Explain

Predict binding & developability

Generate

Predict

Explain

Predict binding

01

01

Generate diverse antibody candidates in silico

Optimized antibody candidates, generated with unprecedented speed and precision through AI-driven molecule design. Define your target and optional constraints, and ConvergeAB uses computational molecule design and affinity maturation to design molecule variants, rapidly producing diverse sequences ranked for binding affinity, structural stability, and functional relevance.

Optimized antibody candidates, generated with unprecedented speed and precision through AI-driven molecule design. Define your target and optional constraints, and ConvergeAB uses computational molecule design and affinity maturation to design molecule variants, rapidly producing diverse sequences ranked for binding affinity, structural stability, and functional relevance.

Start generating

02

02

Better leads,
fewer cycles

Optimize affinity, stability, solubility, immunogenicity, and expression in a single AI-driven molecule design pass. Each lead is derived from millions of in silico designs, ranked and filtered to maximize success and cut lab iterations.

Optimize affinity, stability, solubility, immunogenicity, and expression in a single AI-driven molecule design pass. Each lead is derived from millions of in silico designs, ranked and filtered to maximize success and cut lab iterations.

Start optimizing

03

03

Prioritize high-performing candidates before entering the lab

ConvergeAB screens millions of antibody sequences per target using AI-driven molecule design, scoring each for affinity, developability, epitope specificity, humanization, and structural fit. Clear scores and visual outputs enable confident selection, accelerating discovery and reducing experimental burden.

ConvergeAB screens millions of antibody sequences per target using AI-driven molecule design, scoring each for affinity, developability, epitope specificity, humanization, and structural fit. Clear scores and visual outputs enable confident selection, accelerating discovery and reducing experimental burden.

Start screening

04

04

Generate, optimize and screen - all in one single platform

Each candidate includes rich predictive profiles - affinity, stability, solubility, immunogenicity, and docking-based structural fit - powered by AI-driven molecule design. Review key metrics, explore 3D visualizations, and export top sequences for synthesis, whether you validate in-house or with a CRO, moving forward with confidence and clarity.

Each candidate includes rich predictive profiles - affinity, stability, solubility, immunogenicity, and docking-based structural fit - powered by AI-driven molecule design. Review key metrics, explore 3D visualizations, and export top sequences for synthesis, whether you validate in-house or with a CRO, moving forward with confidence and clarity.

Start designing

Private by design

Only your team can access your data. We don’t share, reuse, or train on it. Your privacy is always protected.

Complete ownership

All sequences and outputs belong to you, with no royalties or restrictions. You have full rights and control.

Fully managed

We handle infrastructure end-to-end, from setup to scaling, so your team can focus entirely on the science.

Expert support

Our scientists and AI experts guide you through every stage, ensuring smooth design and discovery.

How it works

How it works

ConvergeAB™ is trained on over 1 trillion natural protein tokens, including 7 million antibody sequences, 3 million antibody–antigen pairs, and 10,000 developability measurements. This foundation enables affinity maturation, developability optimization, humanization, patent escape and IP expansion, and candidate screening across IgG, ScFv, and VHH (Beta) formats.

Input

Input

You provide the biological elements: a mandatory protein sequence defining the final product, and optional regulatory regions. The promoter controls gene expression strength, while the 5’ and 3’ UTRs influence mRNA stability, translation efficiency, and overall protein yield, all of which can be optimized.

Input

You provide the biological elements: a mandatory protein sequence defining the final product, and optional regulatory regions. The promoter controls gene expression strength, while the 5’ and 3’ UTRs influence mRNA stability, translation efficiency, and overall protein yield, all of which can be optimized.

2nd

Predictors

Predictors

Each predictor scores generated antibodies on key drug-development properties: correct heavy/light chain pairing, binding strength, off-target risk, cellular expression, solubility, thermostability, aggregation risk, and self-association, ensuring selected candidates are potent, stable, and manufacturable.

Predictors

Each predictor scores generated antibodies on key drug-development properties: correct heavy/light chain pairing, binding strength, off-target risk, cellular expression, solubility, thermostability, aggregation risk, and self-association, ensuring selected candidates are potent, stable, and manufacturable.

2nd

Output

Output

After generating and scoring many designs, the system selects a small set of high-confidence antibody candidates that bind strongly, demonstrate developability and manufacturability, and carry lower risk of failure—ready for experimental validation in the lab.

Recent Updates

Resources Page

Case Study

Zero-Shot Design of a Biobetter Cetuximab: Enhancing EGFR Binding with ConvergeAB™

Case Study

Generating Clinic-Ready Antibodies: Benchmarking ConvergeAB™ Against Blockbuster Drugs

Blog

Zero CDR Edits, 2.7× Tighter: What ConvergeAB™ Did to a Clinical Antibody

Recent Updates

Case Study

Zero-Shot Design of a Biobetter Cetuximab: Enhancing EGFR Binding with ConvergeAB™

Case Study

Generating Clinic-Ready Antibodies: Benchmarking ConvergeAB™ Against Blockbuster Drugs

Blog

Zero CDR Edits, 2.7× Tighter: What ConvergeAB™ Did to a Clinical Antibody

Resources Page

pixelized colorful circle

Start designing
better antibodies

Access ConvergeAB

pixelized colorful circle

Start designing
better antibodies

Access ConvergeAB